Antonio Rullan

17PUBLICATIONS
72CO-AUTHORS
Molecular targetsPredictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 01, 2026
Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Randomized Study.

|Jul 30, 2026
"SMAC"-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?

|Apr 27, 2026
Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion.

|Oct 22, 2025
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Charleen Chan Wah Hak, Emmanuel C Patin, Anton Patrikeev

|Sep 26, 2025
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.

Andrew J Hayes, Emma J Davies, Michelle Wilkinson

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

Pageof 3

Frequent Collaborators

9 joint publications

Kevin J Harrington

6 joint publications

Alan Melcher

6 joint publications

Emmanuel Christian Patin

6 joint publications

Charleen Chan Wah Hak